SSW [Seaspan] 6-K: Seaspan Corporation nd Unit 2, 2 141 Connaught

[Seaspan Corporation nd Unit 2, 2 141 Connaught Road West Hong Kong, China c/o 2600 – 200 Granville Street Vancouver, BC Canada V6C 1S4 Tel: 604-638-2575 Fax: 604-648-9782 www.seaspancorp.com Seaspan Announces Public Offering of Series H Cumulative Redeemable Perpetual Preferred Shares Merrill Lynch, Pierce, Fenner & Smith Incorporated, Morgan Stanley, J.P. Morgan, RBC Capital Markets and Citigroup Global Markets Inc.] [Item 1 — Information Contained in this Form 6-K Report SEASPAN CORPORATION David Spivak Chief Financial Officer (Principal Financial and Accounting Officer) 6-K 1 d226290d6k.htm FORM 6-K]

CNIT [China Information Technology] 6-K: FORM 6-K August 2016 001-35722 CHINA INFORMATION TECHNOLOGY,

[FORM 6-K August 2016 001-35722 CHINA INFORMATION TECHNOLOGY, INC. 21 st Floor, Everbright Bank Building Zhuzilin, Futian District Shenzhen, Guangdong, 518040 People’s Republic of China Note Note: On July 29, 2016, Mr. Guanguyuan Zong resigned from his position as Chief Marketing Officer of China Information Technology, Inc. (the “Company”). Mr. Zong’s resignation was due to personal reasons and was not]

By | 2016-08-05T02:50:29+00:00 August 4th, 2016|Categories: Chinese Stocks, CNIT, Webplus ver|Tags: , , , , , |0 Comments

SSW [Seaspan] 424B5: (Original Filing)

[This document is in two parts. The first part is the prospectus supplement, which describes the specific terms of this offering. The second part is the accompanying base prospectus, which gives more general information, some of which may not apply to this offering. Generally, when we refer to the “prospectus,” we are referring to both parts combined. If information in]

CBPO [China Biologic Products] 8-K: (Original Filing)

[FOR RELEASE August 4, 2016 China Biologic Reports Financial Results for the Second Quarter of 2016 --2Q16 Total Sales Up 23.4% with Non-GAAP Net Income Up 31.3% YoY in RMB terms, or Up 15.5% YoY to $91.4 Million and 23.1% YoY to $35.2 Million in USD terms, respectively --1H16 Total Sales Up 26.2% with Non-GAAP Net Income Up 30.6% YoY] []

SSW [Seaspan] 424B5: This document is in two parts. The first

[This document is in two parts. The first part is the prospectus supplement, which describes the specific terms of this offering. The second part is the accompanying base prospectus, which gives more general information, some of which may not apply to this offering. Generally, when we refer to the “prospectus,” we are referring to both parts combined. If information in]

CBPO [China Biologic Products] 8-K: FOR RELEASE August 4, 2016 China Biologic Reports

[FOR RELEASE August 4, 2016 China Biologic Reports Financial Results for the Second Quarter of 2016 --2Q16 Total Sales Up 23.4% with Non-GAAP Net Income Up 31.3% YoY in RMB terms, or Up 15.5% YoY to $91.4 Million and 23.1% YoY to $35.2 Million in USD terms, respectively --1H16 Total Sales Up 26.2% with Non-GAAP Net Income Up 30.6% YoY] []

KGJI [KINGOLD JEWELRY] 8-K: (Original Filing)

[Trust Loan Contract Between China Minsheng Trust Co., Ltd. And Wuhan Kingold Jewelry Co., Ltd. Contract No.: 2016 Trust Loan Contract Lender (Party A): China Minsheng Trust Co., Ltd. Address: 19/F, Tower C, Minsheng Financial Center, No. 28, Jianguo Mennei Road, Dongcheng District, Beijing Zip Code: 100005 Legal Representative: Zhiqiang Lu Fax Number: 010-85259080 Phone Number: 010-85259071 Borrower (Party B):] []

By | 2016-08-05T02:25:32+00:00 August 4th, 2016|Categories: Chinese Stocks, KGJI, SEC Original|Tags: , , , , , |0 Comments

CBPO [China Biologic Products] IRANNOTICE: (Original Filing)

[China Biologic Products, Inc. 18th Floor, Jialong International Building 19 Chaoyang Park Road Chaoyang District, Beijing 100125 People’s Republic of China August 4, 2016 VIA EDGAR 100 F Street, N.E. Re: Notice of Disclosure Filed in Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the]

ONP [Orient Paper] 8-K: (Original Filing)

[Orient Paper, Inc. Announces Unaudited Preliminary Financial Results for Second Quarter 2016 Company to Host Earnings Conference Call on Thursday, August 11, 2016, at 8:00 am ET Selected Second Quarter 2016 Financial Results (Unaudited and Preliminary) For the Three Months Ended June 30, 2016 2015 % Change Revenue ($M) $ 38.0 $ 41.3 -8.0 % Sales volume (tonnes) Regular Corrugating] []

CBPO [China Biologic Products] 10-Q: (Original Filing)

[] [STATE OF DELAWARE THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CHINA BIOLOGIC PRODUCTS, INC. Corporation China Biologic Products, Inc., a corporation organized and existing under the laws of the State of Delaware (the “ The name of the Corporation is China Biologic Products, Inc. The original Certificate of Incorporation of the Corporation was filed with the Secretary of State] [Settlement Agreement This settlement agreement (this “Agreement”) was entered into by and among the following parties (the “Parties,” and each a “Party”) in Yunyan District, Guiyang City, China on July 31, 2016: Party A: Guizhou Taibang Biological Products Co., Ltd. Party B: Guiyang Dalin Biologic Technologies Co., Ltd. Party C: Guizhou Jie’an Company Party D: Shenzhen Yigong Shengda Technology Co.,] [Guarantee Agreement This Guarantee Agreement (this “Agreement”) was entered into by the following parties (the “Parties,” and each a “Party”) at No.808 Meeting Room No. 3 Office Building of Guizhou Province Government in Guiyang City, China on July 31, 2016: Party A: Guizhou Taibang Biological Products Co., Ltd. (“Guizhou Taibang”) Party B: Guiyang Dalin Biologic Technologies Co., Ltd. (“Guiyang Dalin”)] [CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (this “Agreement”) is entered into as of this July 1, 2016 (the “Effective Date”) by and between CHINA BIOLOGIC PRODUCTS, INC., a Delaware corporation (the “Company”) and Mr. Hui (David) Li (hereinafter referred to as the “Consultant”). WHEREAS, NOW, THEREFORE, Senior Strategic and Investment Consulting Agreement 1. provided however Term 2. Compensation 3. (c) Consultant] [Second Amended and Restated Employment Agreement Agreement Company Executive This Second Amended and Restated Employment Agreement (this “ 2012 Agreement WHEREAS, the Company and the Executive entered into an employment agreement dated as of May 11, 2012 (the “ 2014 Agreement WHEREAS, the Company and the Executive entered into a renewal employment agreement dated as of May 11, 2014 (the] [CERTIFICATIONS I, David (Xiaoying) Gao, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATIONS I, Ming Yang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th David (Xiaoying) Gao Chief Executive Officer] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th Ming Yang (Principal Financial and Accounting Officer) Chief Financial Officer]

Skip to toolbar